CCL2 and acute kidney injury: Mechanistically, IRAR positively regulated expressions of chemokine CXCL1, CXCL2 and CCL2 in TECs, and knockdown of IRAR significantly reduced IR-induced immune cells infiltration, inflammatory factors production, and subsequently attenuated acute kidney injury, indicating IRAR as a potential therapeutical target for kidney disease.